Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02325414 · ClinicalTrials.gov registry record · Phase 2

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

A Phase 2 study of Spinal Cord Injury and Osteoporosis, sponsored by Northwestern University.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
2
Study locations

NCT02325414: Completed Phase 2 study of Spinal Cord Injury and Osteoporosis, sponsored by Northwestern University.

NCT02325414 is a Phase 2 study of Spinal Cord Injury and Osteoporosis that has completed, run by Northwestern University. The registered enrollment target is 60 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (30% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02325414, a Phase 2 study of Spinal Cord Injury and Osteoporosis, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.

Primary Outcome

Percent change of bone mass density (BMD) in the total hip (as measured by DXA)

Interventions

  • DRUG Placebo
  • DRUG Zoledronic acid

Study Locations (2)

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago
  • Rehabilitation Institute of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2015-02
Est. Completion 2020-08-25
Phase Phase 2
Northwestern University

1,209 total trials

What the finished NCT02325414 record still lists

NCT02325414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (30% lower).

The record links to 4 conditions, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02325414 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT02325414 about?

NCT02325414 is a clinical study titled "Prevention of Bone Loss After Acute SCI by Zoledronic Acid". The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.

What is the current status of trial NCT02325414?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2015-02. Estimated completion is 2020-08-25.

What conditions does trial NCT02325414 study?

This clinical trial studies the following conditions: Spinal Cord Injury, Osteoporosis, Bone Loss, Acute Spinal Cord Injury.

What interventions are being tested in trial NCT02325414?

The interventions under investigation include: Placebo (DRUG), Zoledronic acid (DRUG).

Who is sponsoring clinical trial NCT02325414?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02325414 being conducted?

This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02325414's enrollment target sits among peer trials

60 32nd of 99 higher than 66 of 99 other Spinal Cord Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02325414, the US trial registry maintained by the National Library of Medicine. NCT02325414 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.